Physician profile
Michael Poon
NPI 1306917331
$2,684.50
in general payments reported to CMS, 2019-2025
25 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $56.25 · 2021: $626 · 2022: $300 · 2023: $303 · 2024: $386 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $105.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valencia Technologies Corporation | $440.99 | 2025 | Ecoin Device Kit |
| Boston Scientific Corporation | $288.23 | 2019-2023 | Rezum Generator |
| Intuitive Surgical, INC. | $257.96 | 2019-2022 | |
| Coloplast Corp | $241.16 | 2021 | |
| Abbvie INC. | $208.08 | 2021-2025 | |
| Teleflex LLC | $165.73 | 2022-2024 | |
| Amgen INC. | $153.19 | 2021-2024 | Enbrel |
| Medtronic, INC. | $151.58 | 2021 | |
| Sumitomo Pharma America, INC. | $129.74 | 2023-2024 | Gemtesa |
| Novo Nordisk INC | $62.10 | 2020-2025 | Wegovy |
| Ucb, INC. | $59.40 | 2025 | Bimzelx |
| Karl Storz Endoscopy-America | $59.26 | 2023 | Flex-X |
| Cook Medical LLC | $58.74 | 2021 | |
| Myriad Genetic Laboratories, INC. | $50.00 | 2025 | Prolaris |
| Axonics, INC. | $49.99 | 2023-2024 | Axonics, Bulkamid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $47.53 | 2023-2025 | Pylarify |
| Astellas Pharma US INC | $46.43 | 2022-2023 | Myrbetriq |
| Blue Earth Diagnostics | $45.63 | 2023 | |
| Smith+Nephew, INC. | $38.33 | 2024 | Stravix Pl |
| Aurinia Pharma U.S., INC. | $28.55 | 2022-2023 | Lupkynis |
| Urogen Pharma, INC. | $25.39 | 2023 | Jelmyto |
| Immunitybio, INC. | $21.74 | 2025 | |
| Janssen Biotech, INC. | $21.22 | 2023 | Tremfya |
| Urovant Sciences INC | $17.98 | 2022 | |
| Glaxosmithkline, LLC. | $15.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Poon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.